title: Small molecule inhibitors of ebola virus infection.
abstract: Ebola viruses are extremely virulent and highly transmissible. They are responsible for sporadic outbreaks of severe hemorrhagic fevers with human mortality rates of up to 90%. No prophylactic or therapeutic treatments in the form of vaccine, biologicals or small molecule, currently exist. Yet, a wealth of antiviral research on ebola virus is being generated and potential inhibitors have been identified in biological screening and medicinal chemistry programs. Here, we detail the state-of-the-art in small molecule inhibitors of ebola virus infection, with >60 examples, including approved drugs, compounds currently in clinical trials, and more exploratory leads, and summarize the associated in vitro and in vivo evidence for their effectiveness.
authors.affiliation: Medicinal Chemistry, Taros Chemicals GmbH & Co. KG, Emil-Figge-Str. 76a, 44227 Dortmund, Germany.
authors.forename: Edwige
authors.initials: E
authors.lastname: Picazo
authors.affiliation: Medicinal Chemistry, Taros Chemicals GmbH & Co. KG, Emil-Figge-Str. 76a, 44227 Dortmund, Germany. Electronic address: fgiordanetto@tarosdiscovery.com.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Giordanetto
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D029043:Ebolavirus / Q000187:drug effects / Q000502:physiology; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology; D006801:Humans; D053586:Virus Internalization / Q000187:drug effects
chemical_list: D000998:Antiviral Agents